SEC Form 4 · accession 0000899243-18-015721
T2 Biosystems, Inc. · TTOO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
John McDonough
Officer — President & CEO · Director
Period of report
Feb 9, 2018
Accepted (ET)
Jun 8, 2018 · 3:53 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001492674
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Feb 9, 2018 | S | 6,292 | $4.28 | D | 262,834 | D | |
| Common Stock | Jun 6, 2018 | A | 33,130 | $0.00 | A | 295,964 | D | |
| Common Stock | Jun 6, 2018 | F | 10,751 | $8.53 | D | 285,213 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Includes 5,106 shares acquired under the Issuer's employee stock purchase on May 15, 2018, and 16,667 shares acquired on February 9, 2018, upon vesting and conversion on a one-to-one basis of restricted stock units granted to the reporting person on February 9, 2017.